BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/29/2022 6:42:52 AM | Browse: 403 | Download: 683
 |
Received |
|
2021-10-19 02:29 |
|
Peer-Review Started |
|
2021-10-19 02:31 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-12-03 20:24 |
|
Revised |
|
2022-01-07 16:01 |
|
Second Decision |
|
2022-03-22 06:37 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2022-03-27 05:33 |
|
Articles in Press |
|
2022-03-27 05:33 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2022-04-01 14:15 |
|
Publish the Manuscript Online |
|
2022-04-29 06:42 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Radiology, Nuclear Medicine & Medical Imaging |
| Manuscript Type |
Minireviews |
| Article Title |
Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Neil Grey, Michael Silosky, Christopher H Lieu and Bennett B Chin |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Bennett B Chin, MD, Professor, Department of Radiology, University of Colorado School of Medicine, Anschutz Medical Campus, 12401 East 17th Avenue, Mail Stop L954A, Aurora, CO 80045, United States. bennett.chin@cuanschutz.edu |
| Key Words |
DOTATATE; Theranostics; Gastroenteropancreatic neuroendocrine tumors; 68Ga DOTATATE; 177Lu DOTATATE; Review |
| Core Tip |
68Ga and 64Cu DOTATATE positron emission tomography imaging is the most sensitive and accurate method to identify well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The paired therapeutic radiotracer, 177Lu DOTATATE, delivers targeted radiation which can prolong progression free survival. This is now established as the therapeutic best standard of care for patients with progressive, metastatic, or unresectable well-differentiated somatostatin receptors positive GEP-NETs. Ongoing investigations continue to expand the potential indications for DOTATATE theranostics. Additional novel ligands are also currently being developed for targeted imaging and therapy of GEP-NETs. |
| Publish Date |
2022-04-29 06:42 |
| Citation |
Grey N, Silosky M, Lieu CH, Chin BB. Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors. World J Gastroenterol 2022; 28(17): 1768-1780 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i17/1768.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i17.1768 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
